Compare First Solar, Inc. (FSLR) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Solar, Inc. vs Moderna, Inc. — how do they compare? First Solar, Inc. trades at $177.82 (market cap $19.22B), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 4.1× First Solar, Inc.'s market cap, and Moderna, Inc. is trading nearer its 52-week high, First Solar, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold First Solar, Inc. for 76 Days and Moderna, Inc. for 59 Days on average.
| FSLR | MRNA | |
|---|---|---|
Market Cap | $19.22B | $78.65B |
Volume | 2,067,793 | 37,373,437 |
Sector | Energy | Health |
52-Week High | $318.30 | $203.46 |
52-Week Low | $172.11 | $22.36 |
Typical Hold Time | 76 Days | 59 Days |
Enterprise Value | $17.69B | $74.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Solar (FSLR) trades at $178.85, down 0.71% on the day, with a bearish technical signal and key support at $175. Fundamentally, the company shows strong profitability with a 32.47% net income margin and robust revenue growth, though it recently missed Q4 2025 EPS estimates. Recent news includes a patent lawsuit filing and elevated put option activity, reflecting mixed sentiment amid sector-wide pressures from high borrowing costs.
The outlook balances solid fundamentals against near-term headwinds. Analyst consensus is bullish with a $267.59 price target, but risks include solar industry volatility, interest rate sensitivity, and competitive challenges. Earnings growth and execution on guidance are critical for stock performance.
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Solar, Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
